The availability of the extended clinical findings from CTSC mutation carriers, as provided by the CTSCbase, is critical for furthering both our understanding of the disease and the development of causative therapies that will be more specific and effective than the symptomatic treatments currently available for patients with PLS, HMS, and AP1 variants. This evidence concerns the gene CTSC and Haim-Munk syndrome.